Twenty-four amino acids encoded inside mitochondrial DNA. Discovered by accident in 2001 while scientists were looking for something that could protect brain cells from Alzheimer's damage. And it is one of the first peptides ever shown to extend lifespan in animals by activating cellular cleanup.
🔑 Key Takeaways
- Humanin is a 24-amino-acid peptide encoded by the MT-RNR2 gene inside the mitochondrial DNA. Unlike most peptides that come from nuclear-encoded genes, Humanin originates in mitochondria and is the first mitochondrial-derived peptide (MDP) identified
- Discovered in 2001 by Dr. Yuichi Hashimoto in Dr. Ikuo Nishimoto's lab while screening for neuroprotective factors against amyloid-beta toxicity. Later independently identified in labs studying BAX protein and IGFBP3 interactions
- Primary mechanism is anti-apoptotic: Humanin binds and neutralizes pro-apoptotic proteins (BAX, tBID) and activates cell-survival signaling through a tripartite receptor complex (gp130 / WSX1 / CNTFR)
- Extends lifespan in C. elegans through autophagy activation (the cellular cleanup process). This is the first peptide to show a lifespan extension mechanism involving autophagy
- Active research areas: Alzheimer's disease, Huntington's disease, stroke, cardiovascular disease (atherosclerosis, heart failure), type 1 and type 2 diabetes, pancreatic beta cell survival, oxidative stress protection
- Synthetic analogs HNG (Humanin-G) and HNGF6A are 1,000 to 10,000 times more potent than the native peptide and are used in most research studies. The peptide sold commercially is typically one of these analogs
- Typical community dose is 0.5 to 2 mg subcutaneously, often weekly rather than daily. Cycling is standard. No FDA approval
- Side effects are mild and uncommon in published animal studies and community reports. Long-term human safety data does not exist
This page is the full 2026 reference on Humanin peptide: discovery, chemistry, mechanism, every documented benefit, community dosing, side effects, contraindications, comparison to other longevity peptides including MOTS-c, and research status.
What Is Humanin?
A mitochondrial-derived peptide with unusually wide-ranging effects.
Humanin is a 24-amino-acid peptide with the sequence MAPRGFSCLLLLTSEIDLPVKRRA. Its chemical formula is C119H204N34O32S2 and its molecular mass is about 2,687 g/mol. What makes it unusual among peptides is its origin: it is encoded by a gene (MT-RNR2) that sits inside mitochondrial DNA, specifically within the 16S ribosomal RNA gene. This places it in a small class of molecules called mitochondrial-derived peptides (MDPs). Humanin was the first MDP ever identified, in 2001.
Humanin at a Glance
- Chemical name: Humanin (HN)
- Sequence (24-aa cytosolic): MAPRGFSCLLLLTSEIDLPVKRRA
- Sequence (21-aa mitochondrial): Shorter variant, still biologically active
- Gene: MT-RNR2 (mitochondrial DNA, within 16S rRNA gene)
- Molecular formula: C119H204N34O32S2
- Molar mass: ~2,687 g/mol
- Structure: Three-turn alpha-helix
- Synthetic analogs: HNG (S14G-substitution, 1,000x potency), HNGF6A (10,000x potency)
- Discovery: 2001, Hashimoto / Nishimoto lab (Keio University, Japan)
- Also identified by: Reed lab (BAX interaction), Pinchas Cohen lab (IGFBP3 interaction)
The synthetic analog detail matters. Native Humanin is biologically active but not very potent in pharmacological doses. HNG (Humanin-G, with a single glycine substitution at position 14) is about 1,000 times more potent than native Humanin. HNGF6A is roughly 10,000 times more potent. Most "Humanin" sold as research peptides is actually one of these analogs, which is why community dosing uses milligram rather than microgram ranges.
How Humanin Works
Two mechanism categories, both pointing at cellular survival.
Anti-apoptotic binding
Humanin's original mechanism (and how it was first discovered) is binding and neutralizing pro-apoptotic proteins that normally trigger cell death:
- BAX binding: BAX is a BCL-2 family protein that, when activated, punches holes in the outer mitochondrial membrane to trigger apoptosis (programmed cell death). Humanin binds BAX and prevents its mitochondrial translocation and activation.
- tBID binding: Similar story for tBID, another pro-apoptotic BCL-2 family member.
- IGFBP3 interaction: Humanin binds insulin-like growth factor binding protein 3, which is involved in both apoptosis signaling and IGF-1 regulation.
The net effect is that cells exposed to stress signals that would normally trigger apoptosis (amyloid-beta toxicity, oxidative stress, ischemia) survive instead. This is the core protective action.
Receptor-based survival signaling
Humanin also works through a tripartite extracellular receptor complex composed of three proteins:
- gp130: The common signaling subunit for the IL-6 cytokine family
- WSX1: A receptor subunit related to IL-27 signaling
- CNTFR: Ciliary neurotrophic factor receptor
When Humanin binds this tripartite complex on a cell surface, it activates downstream pro-survival signaling pathways (PI3K/Akt, MAPK/ERK, STAT3). These are the same pathways that many growth factors and cytokines use to keep cells alive and healthy.
A separate receptor, formyl peptide receptor 2 (FPR2), also binds Humanin and contributes to anti-inflammatory effects.
Autophagy activation (the longevity link)
The most recently characterized mechanism. Humanin activates chaperone-mediated autophagy (a selective form of cellular cleanup where damaged proteins are trafficked to lysosomes for degradation) in a dose-dependent way. Autophagy is one of the central mechanisms through which caloric restriction, rapamycin, and fasting extend lifespan. Humanin is one of the few peptides to tap into this same pathway.
In C. elegans studies, Humanin extends lifespan through an autophagy-dependent mechanism. Blocking autophagy eliminates the lifespan extension effect, which establishes autophagy as the causal pathway.
Humanin Benefits
Alzheimer's disease protection
The original discovery context. Humanin was identified in a screen for neuroprotective factors against amyloid-beta (Aβ) toxicity in neurons. It protects neurons from Aβ-induced cell death in cell culture and in animal models of Alzheimer's disease. Clinical trials in humans have not been completed, but the mechanistic case is strong.
Neuroprotection beyond Alzheimer's
Similar protective effects have been documented in animal models of Huntington's disease, stroke (ischemia-reperfusion injury), and general oxidative-stress neuronal injury. The anti-apoptotic mechanism applies broadly to neurons under stress.
Cardiovascular disease
Research in animal models has shown Humanin reduces atherosclerotic plaque formation, protects cardiac muscle against ischemia-reperfusion injury, and may improve outcomes in heart failure models. The mechanism is cardiac myocyte survival via the anti-apoptotic and receptor-based signaling pathways.
Type 1 and type 2 diabetes
Pancreatic beta cells (the insulin-producing cells destroyed in type 1 diabetes and stressed in type 2 diabetes) respond to Humanin with improved survival and function. Animal models have shown Humanin administration preserves beta cell mass and improves insulin sensitivity.
Longevity and lifespan extension
The C. elegans lifespan extension finding is the headline longevity result. Humanin levels naturally decline with age in humans and other species, and this decline correlates with age-related disease risk. Whether exogenous Humanin extends lifespan in mammals (including humans) is unknown and would take decades of trials to establish, but the animal evidence is compelling enough to support the peptide's longevity research interest.
Oxidative stress protection
Humanin broadly protects cells against oxidative damage, part of the general anti-apoptotic effect. This applies to multiple tissues including brain, heart, kidney, and pancreas.
Anti-inflammatory effects
Reduces pro-inflammatory cytokine production, likely mediated through the FPR2 receptor. Relevant for chronic inflammatory disease states.
Humanin Dosage
All injection-based. Community protocols reference the potent HNG analog rather than native Humanin.
Standard Humanin Protocol
- Typical dose: 0.5 to 2 mg subcutaneously
- Frequency: Weekly (most common) or daily low-dose (0.5 mg)
- Cycle length: 4 to 8 weeks
- Break: 2 to 4 weeks between cycles
- Cycles per year: 2 to 4
- Timing: Morning injection, subcutaneous into abdomen, thigh, or upper arm. Rotate sites
No FDA-approved dose exists because there is no FDA approval. Dosing is extrapolated from animal research adjusted for body weight and from community practitioner reports. Most users start at 0.5 mg weekly and adjust based on response.
Reconstitution
Humanin is sold as a lyophilized powder, typically in 5 mg or 10 mg vials. A 5 mg vial reconstituted with 1 mL bacteriostatic water gives 5 mg/mL. A 1 mg dose is 20 units on a standard U-100 insulin syringe. Use our reconstitution calculator for other vial sizes.
Storage
- Lyophilized vial: Refrigerate at 2 to 8°C
- Reconstituted: Refrigerate. Use within 4 to 6 weeks
- Protect from light. Do not freeze
Humanin Side Effects
Clean profile in animal studies and community reports.
| Side effect | Frequency | Notes |
|---|---|---|
| Injection site reaction | Occasional | Mild redness or soreness. Rotate sites |
| Mild fatigue (first few doses) | Uncommon | Transient, resolves with continued use |
| Mild headache | Uncommon | Usually first week, resolves with hydration |
| Hypoglycemia sensitivity | Rare | Monitor if you are on insulin or sulfonylureas, since Humanin affects insulin sensitivity |
No human clinical trials have been completed, so long-term safety data is not available. Toxicity studies in animal models have been clean at many multiples of the human-equivalent therapeutic range.
Who Should Not Use Humanin
Do NOT Use Humanin If You:
- Are pregnant or active breastfeeding (no safety data)
- Are under 18 (no pediatric data)
- Have active cancer (precautionary, because the anti-apoptotic mechanism could theoretically protect tumor cells)
- Have known hypersensitivity to Humanin or any component of the formulation
- Are on chemotherapy that relies on inducing apoptosis (consult oncologist before use)
- Are on insulin or sulfonylureas, without physician supervision (potential hypoglycemia due to insulin sensitivity changes)
Humanin vs MOTS-c and Other Longevity Peptides
| Peptide | Origin | Primary mechanism | Best for |
|---|---|---|---|
| Humanin | Mitochondrial DNA (MT-RNR2) | Anti-apoptotic, autophagy | Neuroprotection, beta cell survival, longevity |
| MOTS-c | Mitochondrial DNA (12S rRNA) | AMPK activation, metabolic reprogramming | Exercise mimicry, metabolic health, fat loss |
| SHLP peptides (1-6) | Mitochondrial DNA | Varies by peptide | Research early-stage |
| Epitalon | Synthetic (Khavinson design) | Telomerase activation, pineal/circadian | Anti-aging, sleep |
| FOXO4-DRI | Synthetic (FOXO4 fragment) | Senolytic (kills senescent cells) | Cellular senescence clearance |
The mitochondrial-derived peptide (MDP) family has expanded since Humanin's 2001 discovery to include MOTS-c, SHLP1 through SHLP6, and a growing list of others. Humanin and MOTS-c are the two best-characterized and the only ones with meaningful community and clinical use. They target overlapping but distinct mechanisms, and stacking them is common in longevity-oriented protocols.
Humanin Stacks
- Humanin + MOTS-c: The mitochondrial-derived peptide longevity stack. Humanin for neuroprotection and beta cell support, MOTS-c for metabolic health and exercise mimicry.
- Humanin + SS-31 (elamipretide): Mitochondrial protection on two angles. SS-31 stabilizes cardiolipin in the inner mitochondrial membrane while Humanin supports cellular survival signaling.
- Humanin + NAD+ precursors (NMN 250 to 500 mg daily or NR 300 to 600 mg): Cellular energy plus anti-apoptotic support. Common longevity stack.
- Humanin + rapamycin (physician-supervised): Autophagy activation through two different pathways. Clinical, not casual use.
- Humanin + Epitalon: Bioregulator plus MDP for combined anti-aging effects.
Avoid combining Humanin with chemotherapy regimens that rely on apoptosis induction, unless coordinated with an oncologist.
Research Status in 2026
Humanin has been the subject of active early research for over two decades. The mechanism is well characterized, the anti-apoptotic protection is replicable across cell and animal studies, and the lifespan extension in C. elegans is established. What has not happened yet is a large Phase 2 or Phase 3 human clinical trial for any specific indication.
The main barriers to clinical development mirror what held back DSIP and other broadly-acting peptides: Humanin's mechanism is multi-target, the effect size for any single indication is modest, patent economics for a native mitochondrial peptide are challenging, and the indications with largest patient populations (Alzheimer's, cardiovascular) require very long and expensive trials. Modified analogs like HNG with improved potency and longer half-life could eventually enter dedicated clinical development, but as of 2026 none have advanced to pivotal trials.
Where to Buy Humanin
Quality markers matter. Most commercial "Humanin" is actually the HNG analog.
- ≥98% purity verified by independent HPLC and mass spectrometry
- Third-party Certificate of Analysis per batch
- Clear labeling: whether the product is native Humanin, HNG, or HNGF6A (potency differs 1,000 to 10,000 fold between these)
- Lyophilized vials of 5 or 10 mg
- US-based manufacturing with cold-chain handling
Avoid unlabeled products that do not specify the analog form. For a broader vendor vetting walkthrough, see our best legit peptide vendors guide.